CDCA2 and diffuse large B-cell lymphoma: Further investigation of additional clinical DLBCL cohorts could provide more information on the predictive biomarker potential of CDCA2, yet the REMoDL-B trial is, to our knowledge, the only comprehensive study of bortezomib treatment in DLBCL.